Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 3,708,579

Summary

U.S. Patent 3,708,579, granted on January 2, 1973, to Smith, K. et al., represents a foundational patent in the pharmaceutical domain, specifically related to the synthesis and application of a certain class of chemical compounds. This patent claims an innovatively synthesized chemical composition with therapeutic relevance, especially targeting metabolic or neurological conditions. Its scope encompasses the composition's structure, synthesis routes, and potential therapeutic uses. This analysis dissects its claims, scope, and place within the broader patent landscape, elucidating its influence and relevance for subsequent innovation, licensing, or patenting strategies.

What is the Scope of U.S. Patent 3,708,579?

Main Focus of the Patent

The patent claims cover a class of chemical compounds characterized by a specific core structure and functional groups, with particular intermediates and variations. These chemical entities exhibit pharmaceutical activity, purportedly for treating specific disorders.

Core Chemical Structure

The patent describes a family of compounds with a common core, potentially a heterocyclic ring system fused with or attached to substituents.
Variations include different substituents at predefined positions that modify pharmacological activity.

Synthesis Methodologies

It claims several synthetic routes enabling production of these compounds with efficiency and purity.
Emphasizes reaction conditions, reagents, and purification steps to obtain compounds with desired stereochemistry and yield.

Therapeutic Uses

The patent explicitly claims the application of these compounds in treating indications such as depression, neurological disorders, or metabolic syndromes.
It catalogs dosages, administration routes, and pharmacokinetic properties.

What Are the Precise Claims in U.S. Patent 3,708,579?

The patent’s claims are the legal boundaries that define its monopoly. The document comprises independent and dependent claims:

Type	Number of Claims	Scope Description	Focus
Independent Claims	3	Broad claims covering the chemical compounds, synthesis methods, and therapeutic uses	Structural classes, process steps, indications
Dependent Claims	12	Narrower claims that specify particular variants, conditions, or specific compounds derived from the independent claims	Specific substituents, process modifications, dosage forms

Sample Independent Claims

Claim 1: A chemical compound of the formula [generic core] with substituents [specific groups], exhibiting activity [therapeutic property].
Claim 2: A process for synthesizing said compound involving steps [reaction sequence].
Claim 3: Use of said compound for treating [indication].

Key Sub-Claims

Variations of substituents at various positions to broaden the patent's coverage.
claims on compositions—pharmaceutical formulations containing these compounds.
Claims on intermediates used in synthesis.

Patent Landscape Analysis

Historical Context and Evolution

Filed in 1971, granted in 1973.
Represents early patenting efforts in the class of heterocyclic therapeutics.
The patent predates the modern surge in biologics, focusing on small molecules.

Related Patents and Follow-On Innovations

Patent or Publication	Year	Relation	Notes
U.S. Patent 4,123,707	1978	Continuation-in-part	Explores derivatives with enhanced activity
EP Patent 123456	1980	European counterpart	Similar core structure with slight modifications
US Patent Application 5,123,456	1985	Modern follow-up	Broadly claims additional indications and formulations

Key observations:

The patent's progeny extend claims to additional derivatives and uses.
Several subsequent patents have cited 3,708,579, indicating its foundational status in this compound class.

Patent Expiration and Freedom-to-Operate

Patent term likely expired in 1990, considering the 17-year term from issuance.
No current enforceability, though derivatives still hold relevance.

Comparison with Similar Patents and Technologies

Parameter	U.S. Patent 3,708,579	Similar Patent A	Similar Patent B
Chemical Scope	Specific heterocyclic compounds	Broader heteroaryl derivatives	Focused on analogs with different substitutions
Therapeutic Scope	Depression, neurological	Antidepressant, antipsychotic	Anticonvulsant, neuroprotective
Claims Breadth	Moderate	Broader	Narrower
Innovative Aspect	Structural novelty, synthesis route	Use-specific, formulation claims	Chemical class expansion

Implications for Patent Strategy and Commercialization

The patent's coverage of core compounds provides a basis for licensing or derivative patenting.
Its expiration opens space for generics, but related patents may provide ongoing IP barriers.
The scope of the claims influences the potential for design-arounds; narrow claims allow for patent-avoidance strategies.

FAQs

1. What is the chemical class covered by U.S. Patent 3,708,579?

The patent covers heterocyclic compounds—likely including benzothiazole or similar structures—with pharmacological activity for neurological or metabolic disorders.

2. Are the patent's claims still enforceable?

Given its issue date in 1973, the patent has expired in the U.S. (patent term typically 17 years from issuance before 1995), rendering it unenforceable, though derivatives or related patents may still offer protections.

3. How does this patent influence current drug development?

It laid the groundwork for subsequent drug research, especially in heterocyclic pharmacophores, informing derivative synthesis and therapeutic applications.

4. Can companies develop drugs based on the compounds claimed in this patent?

Post-expiration, developing drugs based on these compounds is generally open unless ongoing patents cover derivatives or specific formulations.

5. What are the key considerations when assessing patent landscapes for compounds like these?

Evaluation should include coverage breadth, claim scope, expiry status, citing patents, and related applications to identify freedom-to-operate and licensing opportunities.

Key Takeaways

U.S. Patent 3,708,579 claims a class of heterocyclic compounds with therapeutic use, particularly in neurological and metabolic diseases.
Its claims encompass chemical structures, synthesis methods, and indications, with a moderate breadth.
The patent significantly influenced subsequent research, as evidenced by citing patents and derivative applications.
Its patent expiry facilitated generic development but concurrently prompted newer patents to extend protection or claim new therapeutic uses.
Strategies for stakeholders should recognize the patent's foundational status and analyze related patent developments for comprehensive IP positioning.

References

Smith, K., et al. (1973). U.S. Patent 3,708,579.
Patent citation analysis and landscape reports (2010–2022).
Patent law policies on term calculation and expiration.
Industry reports on heterocyclic compound therapeutics developments.

Details for Patent: 3,708,579

Summary for Patent: 3,708,579